

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5659450

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
VICTORY PARK MANAGEMENT, LLC	04/25/2013

RECEIVING PARTY DATA

Name:	UNIGENE LABORATORIES, INC.
Street Address:	110 LITTLE FALLS ROAD
City:	FAIRFIELD
State/Country:	NEW JERSEY
Postal Code:	07004

PROPERTY NUMBERS Total: 23

Property Type	Number
Patent Number:	8377863
Patent Number:	8513183
Patent Number:	8664178
Patent Number:	8592366
Patent Number:	8093207
Patent Number:	8088734
Patent Number:	8227241
Patent Number:	8216822
Patent Number:	8835161
Patent Number:	8163871
Patent Number:	8815583
Application Number:	12459385
Patent Number:	8252580
Patent Number:	8076291
Patent Number:	8217139
Application Number:	12732081
Application Number:	13238801
Patent Number:	8378067
Application Number:	13342133
Patent Number:	9102753

PATENT

Property Type	Number
Patent Number:	8497347
Application Number:	61554771
Application Number:	61578620

CORRESPONDENCE DATA

Fax Number: (617)897-0909

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6173106009

Email: BOSIPMAIL@GTLAW.COM

Correspondent Name: DAVID J. DYKEMAN

Address Line 1: GREENBERG TRAUERIG, LLP

Address Line 2: ONE INTERNATIONAL PLACE, SUITE 2000

Address Line 4: BOSTON, MASSACHUSETTS 02110

NAME OF SUBMITTER: DAVID J. DYKEMAN

SIGNATURE: /David J. Dykeman, Reg. No. 46,678/

DATE SIGNED: 08/08/2019

Total Attachments: 3

source=PatentSecurityRelease09212012#page1.tif

source=PatentSecurityRelease09212012#page2.tif

source=PatentSecurityRelease09212012#page3.tif

TERMINATION AND RELEASE OF SECURITY INTEREST

THIS TERMINATION AND RELEASE OF SECURITY INTEREST is made *nunc pro tunc*, and effective as of the April 25, 2013 between Unigene Laboratories, Inc., a Delaware corporation having its principal place of business at 110 Little Falls Road, Fairfield, NJ 07004 (the "Grantor"), and Victory Park Management, LLC (the "Collateral Agent").

WHEREAS Collateral Agent was the owner of a security interest granted by Grantor pursuant to a Pledge and Security Agreement dated September 30, 2008 as referenced in the Patent Security Agreement dated September 21, 2012, previously recorded in the United States Patent and Trademark Office at Reel/Frame No. 029074/0689 on October 4, 2012 on certain assets including the property listed in Schedule A annexed hereto, such security interest is released by the Collateral Agent. For the avoidance of doubt and to ensure that such property is unencumbered by such security interest, Collateral Agent herein cancels, removes and releases said security interest, lien and/or encumbrance, from the following property listed on Schedule A annexed hereto, together with any reissues, reexaminations, continuations, continuations-in-part, divisionals, renewals, extensions thereof and any foreign equivalent patents and patent applications thereof.

NOW, THEREFORE, Collateral Agent hereby forever and fully releases and discharges its lien and/or encumbrance on and security interests in the aforementioned property listed on Schedule A annexed hereto.

Victory Park Management, LLC

By  _____
Scott Zennick

Its Manager

Date July 23, 2019

**SCHEDULE A
TERMINATION AND RELEASE OF SECURITY INTEREST
PATENTS/PATENT APPLICATIONS**

TITLE	COUNTRY	APPLICATION/ PATENT NO.
Peptide Pharmaceutical for Oral Delivery	US	12/128,210 filed 5/28/08 8,377,863 issued 2/19/13
Peptide Pharmaceutical for Oral Delivery	US	13/283,055 filed 10/27/11 8,513,183 issued 8/20/13
Peptide Pharmaceutical for Oral Delivery	US	13/487,784 filed 6/4/12 8,664,178 issued 3/4/14
Peptide Pharmaceutical for Oral Delivery	US	13/487,856 filed 6/4/12 8,592,366 issued 11/6/13
Fast-Acting Oral Peptide Pharmaceutical Products	US	11/567,454 filed 12/6/06 8,093,207 issued 1/10/12
Oral Delivery of Peptides	US	10/761,481 filed 1/20/04 8,088,734 issued 1/3/12
Bacterial Host Cell for the Direct Expression of Peptides	US	11/076,260 filed 3/9/05 8,227,241 issued 7/24/12
Bacterial Host Cell for the Direct Expression of Peptides	US	11/928,936 filed 10/30/07 8,216,822 issued 7/10/12
Bacterial Host Cell for the Direct Expression of Peptides	US	13/544,228 filed 7/9/12 8,835,161 issued 9/16/14
Enzymatic Reactions in the Presence of Keto Acids	US	12/284,552 filed 9/22/08 8,163,871 issued 4/24/12
Cell Lines for Expressing Enzyme Useful in the Preparation of Amidated Products	US	11/474,159 filed 6/23/06 8,815,583 issued 8/26/14
Nasal Calcitonin Formulation	US	12/459,385 filed 6/29/09 RE43,580 issued 8/14/12
Bacterial Host Cell for the Direct Expression of Peptides	US	11/928,994 filed 10/30/07 8,252,580 issued 8/28/12
Treatment for Obesity	US	12/692,502 filed 1/22/10 8,076,291 issued 12/13/11
Treatment for Obesity	US	13/295,906 filed 11/14/11 8,217,139 issued 7/10/12
Peptide Pharmaceuticals for Nasal Delivery	US	12/732,081 filed 3/25/10
Calcitonin Products and Therapies for Treating	US	13/238,801 filed 9/21/11

TITLE	COUNTRY	APPLICATION/ PATENT NO.
Inflammatory or Degenerative Diseases		
Treatment for Obesity	US	13/295,936 filed 11/14/11 8,378,067 issued 2/19/13
Oral Delivery of Peptides	US	13/342,133 filed 1/02/12
Anti-Inflammatory Pharmaceutical Products	US	13/524,381 filed 6/15/12 9,102,753 issued 8/11/15
Methods of Treating Medical Conditions Using Calcitonin Analogs	US	13/544,256 filed 7/9/12 8,497,347 issued 7/30/13
Treatment for Obesity	US	61/554,771 filed 11/2/11
Treatment for Obesity and Type II Diabetes	US	61/578,620 filed 12/22/11